Payment overview · 2025
General Payments
$1,671.14
97 reported records · 18 companies
Healthcare provider profile · identity verified
Amber Dawn Mahar, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · SALLISAW, OK · NPI 1982203444
Verified facts
What the public records show
CMS Open Payments records show Amber Dawn Mahar, APRN received $1,671.14 in general payments during 2025 across 97 reported records.
Novo Nordisk Inc accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Nurtec Odt, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $255.46 | 15.3% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $212.34 | 12.7% | 19 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $164.20 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.67 | 9.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.30 | 9.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.76 | 7.8% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $119.57 | 7.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $103.09 | 6.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.68 | 4.6% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $65.75 | 3.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.46 | 3.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.22 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.30 | 1.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.30 | 1.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.51 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.38 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.19 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.96 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,671.14 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $182.41 | 17 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $164.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.30 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $148.66 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.89 | 6 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $119.57 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $108.96 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.80 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $103.09 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.85 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $65.75 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.46 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.92 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 186 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 145 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 34 |
| Omeprazole | Omeprazole | 103 | 30 |
| Meloxicam | Meloxicam | 102 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 44 |
| Tramadol Hcl | Tramadol Hcl | 85 | 35 |
| Lisinopril | Lisinopril | 79 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 74 | 24 |
| Trazodone Hcl | Trazodone Hcl | 70 | 19 |
| Metformin Hcl | Metformin Hcl | 69 | 24 |
| Potassium Chloride | Potassium Chloride | 67 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 51 |
| Buspirone Hcl | Buspirone Hcl | 59 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 21 |
| Furosemide | Furosemide | 56 | 23 |
| Alprazolam | Alprazolam | 54 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 45 |
| Mounjaro | Tirzepatide | 51 | 15 |
| Methylprednisolone | Methylprednisolone | 50 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Pregabalin | Pregabalin | 42 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 11 |
| Losartan Potassium | Losartan Potassium | 41 | 15 |
| Carvedilol | Carvedilol | 40 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 14 |
| Azithromycin | Azithromycin | 39 | 36 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | 12 |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Cefdinir | Cefdinir | 34 | 32 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 25 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | 12 |
| Methocarbamol | Methocarbamol | 30 | 12 |
| Prednisone | Prednisone | 30 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Cephalexin | Cephalexin | 26 | 18 |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Mupirocin | Mupirocin | 24 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Ozempic | Semaglutide | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Simvastatin | Simvastatin | 23 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,671.14 · 97 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, COBENFY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, GEMTESA, GLASSIA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error